Ian Mortimer
Director, PRESIDENT & CEO · 3 filings · Latest: Sep 30, 2026
Xenon Pharmaceuticals Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
XENE | Ian Mortimer | Director, PRESIDENT & CEO | Sep 30, 2026 | Purchase | $37.38 | 30,000 | $1.1M | 49,923 | |
XENE | Ian Mortimer | Director, PRESIDENT & CEO | Mar 13, 2026 | Sale | $55.23 | 7,308 | $403.6K | 19,923 | |
XENE | Ian Mortimer | Director, PRESIDENT & CEO | Mar 12, 2026 | Option Exercise | — | 12,500 | — | 27,231 | |
XENE | IAN MORTIMER | — | Mar 13, 2026 | Proposed Sale | $55.22 | 7,308 | $403.6K | — | |
XENE | Ian Mortimer | Director, PRESIDENT & CEO | Mar 10, 2026 | Sale | $60.11 | 11,269 | $677.4K | 14,731 | |
XENE | Ian Mortimer | Director, PRESIDENT & CEO | Mar 9, 2026 | Sale | $60.33 | 270,000 | $16.3M | 6,000 | |
XENE | Ian Mortimer | Director, PRESIDENT & CEO | Mar 9, 2026 | Option Exercise | $6.28 | 290,000 | $1.8M | 26,000 | |
XENE | IAN MORTIMER | — | Mar 10, 2026 | Proposed Sale | $60.11 | 11,269 | $677.4K | — | |
XENE | IAN MORTIMER | — | Mar 9, 2026 | Proposed Sale | $60.33 | 270,000 | $16.3M | — | |
XENE | IAN MORTIMER | — | Jan 2, 2026 | Proposed Sale | $44.43 | 40,000 | $1.8M | — | |
XENE | IAN MORTIMER | — | Dec 8, 2025 | Proposed Sale | $45.73 | 10,830 | $495.2K | — | |
XENE | IAN MORTIMER | — | Dec 5, 2025 | Proposed Sale | $45.03 | 14,375 | $647.4K | — | |
XENE | IAN MORTIMER | — | Nov 28, 2025 | Proposed Sale | $45.01 | 97 | $4.4K | — | |
XENE | IAN MORTIMER | — | Oct 1, 2025 | Proposed Sale | $40.16 | 25,000 | $1.0M | — | |
XENE | IAN MORTIMER | — | Jan 27, 2025 | Proposed Sale | $40.50 | 16,315 | $660.8K | — | |
XENE | IAN MORTIMER | — | Jan 24, 2025 | Proposed Sale | $40.20 | 22,468 | $903.3K | — | |
XENE | IAN MORTIMER | — | Jan 23, 2025 | Proposed Sale | $40.08 | 16,217 | $649.9K | — |